Beacon Pointe Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.5M Buy
89,731
+6,681
+8% +$936K 0.07% 265
2025
Q4
$10.2M Buy
83,050
+50,598
+156% +$6.15M 0.07% 254
2025
Q3
$3.6M Sell
32,452
-3,431
-10% -$390K 0.03% 422
2025
Q2
$3.98M Buy
35,883
+539
+2% +$57.4K 0.04% 360
2025
Q1
$3.96M Sell
35,344
-1,928
-5% -$199K 0.04% 343
2024
Q4
$3.44M Sell
37,272
-4,742
-11% -$427K 0.04% 343
2024
Q3
$3.52M Sell
42,014
-10,340
-20% -$789K 0.04% 360
2024
Q2
$3.59M Sell
52,354
-1,770
-3% -$118K 0.04% 347
2024
Q1
$3.96M Sell
54,124
-8,696
-14% -$669K 0.04% 352
2023
Q4
$5.09M Sell
62,820
-1,164
-2% -$90.6K 0.06% 282
2023
Q3
$4.8M Buy
63,984
+24,477
+62% +$1.88M 0.06% 268
2023
Q2
$3.04M Sell
39,507
-13,752
-26% -$1.1M 0.05% 303
2023
Q1
$4.42M Buy
53,259
+11,267
+27% +$933K 0.08% 230
2022
Q4
$3.6M Buy
41,992
+6,948
+20% +$550K 0.07% 248
2022
Q3
$2.16M Buy
35,044
+1,864
+6% +$118K 0.05% 303
2022
Q2
$2.05M Sell
33,180
-29,884
-47% -$1.85M 0.04% 324
2022
Q1
$3.75M Buy
63,064
+28,991
+85% +$1.85M 0.05% 309
2021
Q4
$2.47M Buy
34,073
+5,071
+17% +$349K 0.06% 227
2021
Q3
$2.03M Buy
29,002
+4,602
+19% +$323K 0.05% 283
2021
Q2
$1.68M Buy
24,400
+20,864
+590% +$1.39M 0.06% 246
2021
Q1
$228K Sell
3,536
-1,020
-22% -$65.8K 0.01% 461
2020
Q4
$265K Buy
+4,556
New +$275K 0.02% 395
2020
Q3
Sell
-4,641
Closed -$356K 410
2020
Q2
$356K Buy
+4,641
New +$356K 0.04% 279

Other funds holding GILD

Beacon Pointe Advisors's GILD Position: Q1 2026 in Review

Beacon Pointe Advisors increased its Gilead Sciences (GILD) stake by 8% in Q1 2026, buying an estimated $936K and bringing the position to 89,731 shares worth $12.5M. The position accounts for 0.07% of the portfolio, ranked #265.

Beacon Pointe Advisors first reported a position in GILD in Q2 2020 and has held it in 23 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Beacon Pointe Advisors held 89,731 shares of Gilead Sciences worth $12.5M as of Q1 2026.
  • Beacon Pointe Advisors bought 6,681 Gilead Sciences shares in Q1 2026, an estimated $936K.
  • Gilead Sciences made up 0.07% of Beacon Pointe Advisors's portfolio in Q1 2026, its #265 holding.
  • Beacon Pointe Advisors first reported a position in Gilead Sciences in Q2 2020 and has held it in 23 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.